Chronic Myeloid Leukemia with Variant Chromosomal Translocations: Results of Treatment with Imatinib Mesylate.

Bhise, R and Purohit, S and Lokanatha, D and Jacob, L and Suresh, TM and Govind Babu, K and Babu, S and Lakshmaiah, KC (2013) Chronic Myeloid Leukemia with Variant Chromosomal Translocations: Results of Treatment with Imatinib Mesylate. [Journal (On-line/Unpaginated)]

Full text available as:

PDF - Published Version
Available under License Creative Commons Attribution No Derivatives.



Objective: To evaluate the efficacy of imatinib in chronic myeloid leukemia patients with variant translocations. Methods: Forty eight chronic myeloid leukemia patients carrying variant translocations and treated with imatinib at our institute were considered for the study. Survival and response rates were evaluated. Results: The median follow up was 48 months(m). Forty three (89.58%) patients achieved complete hematologic response. Thirty one (64.58%) patients achieved complete cytogenetic response and 19(39.58%) achieved major molecular response anytime during their follow up period. Only 18.75% of the patients achieved complete cytogenetic response and major molecular response within the stipulated time frames.The estimated overall survival at 48 m median follow up was 81.2%.The progression free survival was also 81.2% and the event free survival was 79.1%.There was no significant survival difference between low vs intermediate and high risk sokal group. Conclusion: We report suboptimal responses to imatinib in chronic myeloid leukemia with variant translocations. Further studies with imatinib and the newer more active drugs dasatinib and nilotinib are justified.

Item Type:Journal (On-line/Unpaginated)
Keywords:Chronic myeloid leukemia; Imatinib; Variant translocation
Subjects:JOURNALS > Online Journal of Health and Allied Sciences
ID Code:8934
Deposited By: Kakkilaya Bevinje, Dr. Srinivas
Deposited On:04 May 2013 23:09
Last Modified:04 May 2013 23:09

References in Article

Select the SEEK icon to attempt to find the referenced article. If it does not appear to be in cogprints you will be forwarded to the paracite service. Poorly formated references will probably not work.

1. Jabbour E, Kantarjian H. Introduction: chronic myelogenous leukemia (CML). Semin Hematol. 2007;44(1 suppl 1):S1-S3.

2. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243(5405):290-293.

3. Huret JL. Complex translocations, simple variant translocations and Ph-negative cases in chronic myelogenous leukaemia. Genet. Hum 1990; 85(6):565-568

4. Gorusu M, Benn P, Li Z, Fang M. On the genesis and prognosis of variant translocations in chronic myeloid leukemia. Cancer Genet Cytogenet. 2007;173(2):97-106.

5. Richebourg S, Eclache V, Perot C, et al. Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy. Cancer Genet Cytogenet. 2008;182(2):95-102.

6. O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004.

7. Baccarani M, Pane F, Saglio G. Monitoring treatmentof chronic myeloid leukemia. Haematologica. 2008;93(2):161-169.

8. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28-37

9. Branford S, Fletcher L, Cross NC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008;112(8):3330-3338.

10. Muller MC, Erben P, Saglio G, et al. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia. 2008;22:96-102.

11. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-2302.

12. El-Zimaity MM, Kantarjian H, Talpaz M, et al. Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol. 2004;125(2):187-195.

13. Stagno F, Vigneri P, Del Fabro V, et al. Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Acta Oncol. 2010;49(4):506-508.

14. Giulia Marzocchi, Fausto Castagnetti, Simona Luatti,et al.Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapya GIMEMA Working Party on CML analysis. Blood 2011;117:6793-6800.


Repository Staff Only: item control page